 Home > Medical News > Medicines Company News > APL-1202 orally combined with tislelizumab neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) completed the first subject enrollment in phase II clinical trial

APL-1202 orally combined with tislelizumab neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) completed the first subject enrollment in phase II clinical trial

 Last Update: 2022-12-30
 Source: Internet
 Author: User

Tags

pd 1 antibody

new company dahej

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Jiangsu Yahong Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as the "Company") conducted the APL-1202 oral combination with tislelizumab neoadjuvant therapy for muscle-invasive bladder cancer (MIBC), and recently completed the enrollment of the first subject in the phase II clinical trial
.

APL-1202 (trade name Vischko) ® is an orally reversible metaP2 inhibitor with antiangiogenesis, antitumor activity and modulation of tumor immune microenvironment
.
Preclinical studies have shown that APL-1202 in combination with PD-1 monoclonal antibody has shown synergistic effects
on the pharmacodynamic model of bladder cancer.

In June 2021, the company obtained the approval of the US Food and Drug Administration (FDA) for the Phase I/II clinical trial of APL-1202 oral combination tislelizumab as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC), and obtained IND approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China at the end of September 2021
.
The primary objective of this trial was to evaluate the efficacy and safety
of APL-1202 in combination with tislelizumab for preoperative neoadjuvant therapy with MIBC.

In addition, APL-1202 is undergoing two registrational clinical trials, APL-1202 in combination with chemotherapy perfusion for the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with recurrent chemotherapy perfusion and APL-1202 monotherapy for untreated intermediate-risk NMIBC
.
The clinical trial of APL-1202 oral combination with tislelizumab neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) completed the phase I dose escalation trial in November 2022 and entered phase II, and recently completed the enrollment of the first subject
.
In phase I clinical trials, the combination of APL-1202 and tislelizumab showed a good safety profile
.

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.